Evaluation of Medical and Social Care for Elderly Patients, Between Hospital and Home: TEMPORARY ACCOMMODATION Out of Hospitalization by Nursing Home and Long-Term Care Units in Ile-de-France Region (HTSH)

June 10, 2025 updated by: Gérond'if
Prospective, observational, non-interventional, comparative, multicenter RIPH3 study to investigate the impact of HTSH on length of hospital stay in referring services.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a multi-center study involving many hospital departments temporary accommodation at the end of hospitalization in several Nursing home/long term care units in Ile de France region. The temporary accommodation program was designed for elderly people living at home to find an accommodation solution in nursing home to meet a short-term need. Temporary accommodation beds are deployed and perpetuated in the Île-de-France region by the Regional Health Agency, physically grouped together in establishments within units with dedicated staff. The resources allocated to these beds have been increased. The aim of the study is to demonstrate the efficiency of the HTSH circuit, for elderly patients leaving hospital, in their medical and social care and the decision or not to return home. This project is supported by Regional Health Agency (ARS-IDF).

Study Type

Observational

Enrollment (Estimated)

258

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Cormeilles en parisis, France, 95240
        • Not yet recruiting
        • Résidence ZEMGOR
        • Contact:
      • L'Haÿ-les-Roses, France, 94240
      • Melun, France, 77000
        • Not yet recruiting
        • Groupe Hospitalier Sud Ile de France (GHSIF)
        • Contact:
      • Paris, France, 75010
        • Not yet recruiting
        • GHU Lariboisière
        • Contact:
      • Paris, France, 75013
        • Recruiting
        • Broca Hospital
        • Contact:
      • Paris, France, 75015
        • Recruiting
        • USDL Vaugirard, APHP
        • Contact:
      • Rambouillet, France, 78514
        • Not yet recruiting
        • Centre Hospitalier de Rambouillet
        • Contact:
      • Versailles, France, 78157
        • Active, not recruiting
        • Centre Hospitalier De Versailles
      • Villejuif, France, 94800
        • Not yet recruiting
        • Hopital Paul Brousse
        • Contact:
    • Ile de France
      • Paris, Ile de France, France, 94270
        • Recruiting
        • CHU Bicêtre
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

258 subjects in the prospective group. Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.

Description

  • Inclusion Criteria:

    1. Patient selection criteria

      • Patient male or female at least 60 years of age, as initially defined with the Regional Health Agency, discharged from hospital,
      • Oral expression of non opposition to participation in the study, documented in the medical record by the physician,
      • Presenting a defined and feasible plan for returning home,
      • Whose social/medical situation (stabilized) does not allow an immediate return home after hospitalization.

    2. Caregiver selection criteria

      • Person with an unpaid caregiving activity for their relative in HTSH,
      • Person verbally expressing their non-opposition to participating in the study, and documented in the medical record of the patient they are helping,
      • A person who is able to understand the study questionnaires and evaluations, and is able to answer them without the help of a third party.

    3. Professional selection criteria

      • Salaried professional, nursing or not, regularly and directly involved in the HTSH circuit, whether in hospital or in nursing home / long term care units, for at least 6 months,
      • Oral expression of non opposition to participation in the study, documented by the establishment.

  • Non-inclusion Criteria:

    • Be already included in another clinical study,
    • Benefit from a legal protection measure or be unable to express their consent, in accordance with article L1121-8 of the French Public Health Code.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Prospective group
258 subjects in the prospective group
Retrospective group
Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Study to investigate the impact of HTSH on length of hospital stay in referring services
Time Frame: 24 months
The main assessment criterion is based on the average length of stay observed at the end of the study, compared with that of the previous two years, 2021 and 2022, in the referring services.
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Analysis of pathways and plans for returning home
Time Frame: 24 months

Evaluation criteria:

Calculation of the proportion of patients in the life project on admission to nursing home / long term care units and the return home at the end of the stay.
24 months
Analysis of HTSH patient profiles a) Proportion of eligible patients and their comorbidities b) Social profile + main reason for hospitalization of patients admitted to HTSH
Time Frame: 24 months

Evaluation criteria:

Ratio of hospital ward activity data to pre-screening data collected during the study.
24 months
Analysis of discharges and patient outcomes
Time Frame: 24 months
Proportion of patients remaining at home in the medium term Patients' functional outcome after the trial
24 months
Quality of life and caregiver benefit analysis
Time Frame: 24 months
Quality of life assessment
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gérond'if

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2024

Primary Completion (Estimated)

November 20, 2026

Study Completion (Estimated)

November 20, 2027

Study Registration Dates

First Submitted

October 23, 2024

First Submitted That Met QC Criteria

November 5, 2024

First Posted (Actual)

November 7, 2024

Study Record Updates

Last Update Posted (Actual)

June 13, 2025

Last Update Submitted That Met QC Criteria

June 10, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2024-A00023-44

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Elderly Patients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe